Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omnitram in painful diabetic neuropathy
NCT03664921Phase 2Completed
- Sponsor
- Syntrix Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Aug 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic neuropathy comparing Omnitram with Placebo (2 arms). Primary endpoint: Numeric Pain Scale up to 28 days. Started Nov 2018; status: completed.
02
Drugs
desmetramadol
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT03664921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03664921.